What is Sai Parenteral’s Limited IPO
The Sai Parenteral’s Limited IPO GMP aka IPO Grey Market Premium, Kostak rates, and Subject to Sauda rates as of today. Sai Parenteral’s Limited IPO GMP is started in the grey market. Stay tuned for the latest IPO GMP in grey Markets numbers of Sai Parenteral’s Limited IPO.
Sai Parenteral's Limited IPO is an Initial Public Offering (IPO) that allows the pharmaceutical company to list on stock exchanges such as NSE and BSE and make its shares available to the public for the first time.
Sai Parenteral IPO Details (Table)
| Particulars | Details |
| IPO Open Date | 24 March 2026 |
| IPO Close Date | 27 March 2026 |
| Allotment Date | 30 March 2026 (Expected) |
| Listing Date | 2 April 2026 (Tentative) |
| Price Band | ₹372 – ₹392 per share |
| Lot Size | 38 shares |
| Minimum Investment | ₹14,896 (approx) |
| Total Issue Size | ₹400+ crore |
| Fresh Issue | ₹285 crore |
| Offer for Sale (OFS) | ~35 lakh shares |
| Face Value | ₹10 per share |
| Listing Exchange | NSE & BSE |
Objectives of the IPO
| Purpose | Details |
| Expansion | Increase manufacturing capacity |
| R&D Investment | Set up new research facility |
| Debt Reduction | Repay existing borrowings |
| Working Capital | Support daily operations |
| Growth Strategy | Expansion in global markets |
Business Overview:
check Sai Parenteral’s Limited IPOs is a pharmaceutical company primarily engaged in the manufacturing or marketing of the injectable formulations or generic medicines. The company focuses on the producing sterile injectables such as vials, ampoules, and infusion products, which are widely used in hospitals and critical care treatments. Its product portfolio supports both acute and chronic therapies, making it an important player in the healthcare supply chain.
In the sai Parenteral Limited ipo gmp in company also operates in contract development or manufacturing (CDMO) segment, providing manufacturing services to other pharmaceutical companies. This not only helps diversify revenue but also strengthens its position in the pharma value chain. Sai Parenteral ipo has established a presence in the both domestic and international markets, exporting its products to semi-regulated and regulated regions.
The company is supported through modern manufacturing facilities or a strong focus on the quality and compliance, which are essential in the pharmaceutical industry. Going forward, Sai Parenteral’s aims to expand its production capacity, invest in research and development, and capitalize on the growing global demand for affordable medicines, especially in the injectables segment.
FAQ
What is the IPO for Sai Parenteral?
The initial public offering, or IPO, is how Sai Parenteral raises money from the general public by listing its shares on the NSE and BSE.
What is the IPO price range for Sai Parenteral?
Each share is priced between ₹372 and ₹392.
How big is Sai Parenteral's IPO lot?
Investors must apply in multiples of the minimum lot size of 38 shares.
What is the required minimum investment?
At the upper price range, the minimum investment is roughly ₹14,896.
Where will the IPO of Sai Parenteral be listed?
The NSE and BSE will list the IPO.
Conclusion
Sai Parenteral’s IPO GMP presents a promising opportunity for investors looking to tap into the growing pharmaceutical sector, especially the high-demand injectables segment. With a diversified business model, expanding global presence, and clear plans for capacity and R&D growth, the company shows potential for long-term expansion.
However, like any IPO, it comes with risks such as regulatory challenges, competition in generics, and dependence on export markets. While the GMP trend indicates possible listing gains, investors should not rely solely on it and must evaluate the company’s financials and valuation carefully.
Sai Parenteral IPO | IPO Details | IPO GMP Today | Upcoming IPO India | Pharma IPO | Latest IPO 2026